To provide a description of the incidence and outcomes in patients with AATD who are known to have been, or suspected to have been, infected with COVID-19.
To establish whether further research is required on the effects of COVID-19 in patients with AATD.
Adult patients (over 18 years of age) with AATD (PiZZ, PiSZ and other rare variants with AAT level <11micromolar) who have been identified by their national / regional AATD centre as having been infected with COVID-19 (either proven with microbiological or serological testing, or with a clinical diagnosis of COVID-19).
Data will be sourced from routine clinical records. There will be no study visits or investigations performed. Anonymised clinical data will be entered into an electronic Case Report Form. Patient identifiable data will only be visible to the direct clinical care team
Patients will be identified by participating centres using audit of clinical coding records and electronic clinical records. AATD patients will self-report to the site coordinator if they have not attended the hospital for management of an episode of COVID-19 infection.
Data will be obtained from assessments obtained as part of routine clinical management. No follow-up will be conducted.